63 results about "Integrin binding" patented technology

The invention discloses a PEI and targeting peptide modified magnetic nano-carrier and a preparation method and application thereof. The nano-carrier is regular in morphology and uniform in particle size and has good crystallinity and magnetic performance. E5 polypeptide and RGD cyclic peptide on the surface of the nano-carrier are respectively combined with CXCR4 protein and integrin on the surface of a tumor cell, and the nano-carrier and CXCR4 are internalized into lysosome through an integrin-mediated way, so that the target protein CXCR4 is degraded. The PEI in the nano-carrier can load and deliver siRNA into tumor cells to silence the expression of CXCR4 mRNA (messenger Ribonucleic Acid). Through nucleic acid delivery and a protein targeted degradation strategy, the CXCR4 level of tumor cells is jointly reduced, the migration ability of the tumor cells is inhibited, and meanwhile, the anti-tumor effect of M1 type polarization of macrophages is activated.

The invention discloses recombinant humanized XVII type and recombinant humanized I type collagen sequences as well as a synthesis method and application thereof, the recombinant humanized collagen comprises one or more functional sequences in cell integrin binding sites such as R / KGD, GER / K, GVMGFP and DGEA, the molecular weight is 6-14 kDa, and the recombinant humanized collagen simultaneously surrounds an isoelectric point, has hydrophilicity and hydrophobicity, and can be used for preparing the recombinant humanized collagen. Reasonable design is carried out on information such as an antigen epitope, GXY sequence stability, protease degradation sites and the like, so that the recombinant humanized collagen has relatively good stability and also has biological activity of promoting cell proliferation and resisting wrinkles and tightening.

The present invention discloses a recombinant collagen and its use in cartilage repair matrix. The recombinant collagen provided by the present invention comprises a sequence shown in SEQ ID No.1; the amino acid sequence of the recombinant collagen comprises N basic repeating units, and the basic repeating unit contains n1 of the following characteristic amino acid sequences: "G‑Xaa1‑Xaa2‑G‑E‑Xaa3"; the 3' end and the 5' end of the basic repeating unit are connected to form the above-mentioned characteristic amino acid sequence. The recombinant collagen provided by the present invention has a relatively obvious integrin binding activity, has the effects of promoting cell adhesion, proliferation, differentiation, repairing cartilage tissue defects, etc., and has good application prospects.

The present invention relates to application of 64Cu in radionuclide-based cancer therapy in humans. More specifically, the invention relates to 64Cu labeled conjugates for use in the treatment of cancer patients including 64Cu labelled Integrin αVβ3 binding conjugates, such as [64Cu]NODAGA-E[c(RGDyK)]2.

A composition and method comprising an antibody that binds to integrin α3β1 are provided.

The application discloses an integrin-reformed specific heart and muscle targeting AAV9 dominant mutant. The application provides an adeno-associated virus capsid protein, which comprises a targeting peptide containing an amino acid sequence as shown in any one of SEQ ID NO: 1-28. According to the RGD sequence binding with integrin, the polypeptide specific binding principle, the random amino acid carrying and the construction of the diversified AAV capsid library, and the high-throughput screening of the AAV with the suitable capsid structure, the application successfully obtains a new adeno-associated virus vector with high heart and / or muscle transduction efficiency, and the new adeno-associated virus vector exhibits better heart and / or skeletal muscle targeting and transduction efficiency in an animal model, and the off-target expression in non-target tissues is significantly reduced, and the new adeno-associated virus vector has important scientific value and commercial prospect.

The invention provides a fusion protein with high repair capacity, a preparation method and application thereof, and belongs to the technical field of hybrid peptides. The amino acid sequence of the fusion protein is shown as SEQ ID NO.1; the fusion protein is obtained by sequentially connecting the following modules in series: a functional domain 1 of fibronectin, a hydrophilic region 1 of elastin, a functional domain 1 of mussel mucin, a hydrophilic region 2 of elastin, a functional domain 2 of fibronectin, a hydrophilic region 3 of elastin, a functional domain 2 of mussel mucin, a hydrophilic region 4 of elastin and an integrin binding region of elastin. The fusion protein of fibronectin, elastin and mussel mucin is constructed, and the nucleotide sequence of the fusion protein is optimized, so that the relative migration rate of keratinocytes can be obviously improved, the expression quantity of repair-related genes of HaCat cells can be improved, the secretion quantity of skin stimulating factors can be reduced, and the inhibition rate on hyaluronidase can be improved; the skin repairing and relieving capability is improved.

Compositions and methods are provided for selective degradation of integrin, which finds use, for example, in the treatment of fibrosis. Compounds of interest as bifunctional integrin-degrading molecules comprising a TG2 binding moiety linked to an integrin binding moiety.

The invention relates to a ligand targeting neutrophil and neurons as well as a preparation method and application of the ligand. The ligand for targeting the neutrophil and the neuron is prepared from the following raw materials in parts by weight: 30 to 50 parts of DSPE-PEG-Tet1, 2 to 3 parts of ketal thiol with carboxyl groups at two ends and 30 to 50 parts of a neutrophil targeting ligand, the neutrophil targeting ligand is one or more of sialic acid, an anti-CD66b antibody, an anti-CD177 antibody, an anti-CD16b antibody, N-formylmethionine peptide (fMLF) and an analogue thereof, a CXCR1 / CXCR2 binding peptide, an integrin binding peptide, a selectin ligand and lectin. According to the invention, sequential targeting of neutrophile granulocytes-neurons can be realized, target cells of ischemic lesions can be accurately protected, and the improvement effect on the cerebral infarction area of MCAO rats can be obviously enhanced.

Provided is a cell scaffold material that improves the efficiency of introducing molecules into cells.　A cell scaffold material according to the present invention is for introducing molecules into cells, and contains a peptide-containing resin (A) having a synthetic resin part and a peptide part. The peptide part has a first peptide part and a second peptide part. The first peptide part and the second peptide part have different amino acid sequences. The first peptide part can bind to a first integrin, and the second peptide part can bind to a second integrin.

Described herein are fusion proteins which include factor H functional domains and may include VHH domains and integrin binding domains, and the use of such fusion proteins in methods of treatment of focal segmental glomerulosclerosis.

Compositions and methods comprising antibodies that bind to integrin [alpha] 3 [beta] 1 are provided.

Disclosed herein are compounds, pharmaceutical compositions, and methods for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals. Compounds disclosed herein are hexacyclic topoisomerase inhibitor prodrugs, conjugated to an integrin binding moiety via cleavable linkers and / or functional spacers.

The disclosure relates to integrin binding peptides, pharmaceutical compositions comprising the peptides and to uses thereof as therapeutic, diagnostic, imaging and targeting agents.

The present invention belongs to the field of pharmaceutical chemistry, and relates to an N-(benzoyl)-phenylalanine compound used as an α4β7 integrin antagonist, including the pharmaceutical composition and the use, and in particular to a compound represented by general formula (1). The compound exhibits good α4β7 integrin binding inhibitory activity, can be used as a high-efficiency α4β7 integrin antagonist, and used for preventing and / or treating α4β7 integrin-related diseases such as autoimmune diseases and inflammatory diseases.

The invention belongs to the technical field of gene engineering, and discloses recombinant human fibronectin as well as a preparation method and application thereof. The amino acid sequence of the recombinant human fibronectin disclosed by the invention is as shown in SEQ ID NO. 1. The recombinant human fibronectin comprises three fragments which are derived from natural fibronectin and have high hydrophilicity and multiple integrin binding capacity, the fragments are expressed in escherichia coli, and the recombinant human fibronectin with high soluble expression quantity is obtained; the recombinant human fibronectin has high activity of promoting proliferation and migration of human keratinocytes, and has potential application prospects in the aspects of skin repair and wound healing.

Provided herein are compounds including delivery moieties for the selective delivery of a therapeutic and / or an oligonucleotide to the lungs. Also provided herein are compounds including a single delivery moiety for the selective delivery of a therapeutic and / or oligonucleotide to the lungs. Also disclosed herein are novel αvβx integrin ligands, such as ligands that associate with αvβ5, αvβ6, and / or αvβ8 integrins.

The invention provides a molecular self-assembly integrin patch for regulating and controlling mechanical signals of cells as well as a preparation method and application of the molecular self-assembly integrin patch, and an extracellular matrix (ECM) bionic cell patch is constructed through a molecular self-assembly technology. According to the patch, a laminin-derived integrin binding ligand is extended and self-assembled through an N-terminal aromatic amino acid to form a fibrous nano network, and the patch has controllable nano-scale ligand distribution, network viscoelasticity and stability, and can specifically activate integrin beta1 at the top end of MSC (mesenchymal stem cell), so that a mechanical signal is conducted from a cell membrane to a cell nucleus. The process coordinates cytoskeleton reconstruction, nuclear deformation and chromatin rearrangement, and finally drives the MSC to efficiently differentiate into neuron-like cells under the condition of no exogenous gene or chemical induction, so as to express nerve markers such as TUBB3 and present functional characteristics such as spontaneous calcium transient. The cell patch can be widely applied to nerve regeneration, tissue engineering, disease model construction and intelligent biological material development.

The application belongs to the field of medicinal chemistry, and relates to N-(benzoyl)-phenylalanine compounds as alpha4beta7 integrin antagonists, pharmaceutical compositions containing the same and uses thereof. Specifically, the application relates to a compound as shown in general formula (1), which exhibits good alpha4beta7 integrin binding inhibition activity, can be used as an efficient alpha4beta7 integrin antagonist, and is used for preventing and / or treating autoimmune diseases and inflammatory diseases related to alpha4beta7 integrin and the like.

The invention discloses an AAV9 dominant mutant of a specific target heart and muscle based on integrin modification. The invention provides an adeno-associated virus capsid protein which comprises a targeting peptide, and the targeting peptide comprises an amino acid sequence as shown in any one of SEQ ID NO: 1-28. The novel adeno-associated virus vector with high heart and / or muscle transduction efficiency is successfully obtained by combining an RGD sequence with integrin, carrying random amino acid through a polypeptide specific binding principle to construct a diversified AAV capsid library and combining high-throughput screening of AAV with an adaptive capsid structure. In addition, the compound shows better heart and / or skeletal muscle targeting and transduction efficiency in an animal model, meanwhile, off-target expression in non-target tissue is remarkably reduced, and the compound has important scientific value and commercial prospect.

The present disclosure provides antibodies or antigen-binding fragments thereof that bind to alpha5 integrin (e.g., human alpha5 integrin), and uses thereof. In certain embodiments, the disclosed antibodies are humanized antibodies.

To provide an alpha (v) beta (6) integrin (avb6) binding polypeptide.SOLUTION: Disclosed herein are alpha (v) beta (6) integrin (avb6) binding polypeptides and their use in the treatment and detection of tumors and in the treatment of pulmonary fibrosis. In one aspect, a polypeptide comprising a specific amino acid sequence is disclosed, wherein the polypeptide binds to alpha (v) beta (6) integrin (avb6). In one embodiment, the amino acid residue at position 8 is R, the amino acid residue at position 9 is G, and the amino acid residue at position 10 is D.SELECTED DRAWING: Figure 3

A transkingdom platform for the delivery of therapeutics to target cells. The system maintains the export and uptake functions of Inv while modifying its targeting away from β1 integrin to other proteins expressed on the surface of target eukaryotic cells (i.e., a cell surface protein) or chemical moieties (i.e., a cell surface chemical moiety) expressed on the surface of a target eukaryotic cell by replacing D4 and D5 of Inv with a binding domain from a heterologous protein via genetic engineering. These heterologous proteins could be derived from bacterial, fungal, animal, or viral genomes. This engineering would result in the construction of a chimeric Inv protein in which D1-D3 (i.e., the non-binding domains) are fused in frame to an alternative binding domain derived from a heterologous protein. The alternative binding domain would interact with a different cell surface protein or chemical moiety, which can in some instances be referred to as a receptor, on the surface on the surface of a eukaryotic cell, thereby allowing specific targeting to cells independent of Inv's intrinsic β1 integrin binding.

The invention discloses application of Cilengitide and derivatives thereof in preparation of medicines for preventing and treating pericardial calcification, and the main mechanism is that the Cilengitide and derivatives thereof inhibit the differentiation of osteogenic precursor cells migrated to pericardium by inhibiting the combination of AEP (Asparagine Endopeptidase) and integrin, so that the differentiation of the osteogenic precursor cells migrated to the pericardium is inhibited, and the differentiation of the osteogenic precursor cells is inhibited. The compound can be used for preparing drugs for inhibiting pericardial calcification caused by natural aging and pericardial calcification induced by tumor diseases or anti-pericardial calcification drugs for research on aging and heart diseases.

This invention pertains in improved culture methods for culturing and expanding cells, including epithelial and endothelial cells, and obtaining organoids. The invention also pertains to particular integrin-binding peptides and proteins used in such culture methods, carriers coated with such integrin-binding peptides and proteins, and tissue culture systems comprising such carriers.

The present invention provides a fusion protein with high repair ability, a preparation method thereof and an application thereof, belonging to the technical field of hybrid peptides. The amino acid sequence of the fusion protein is as shown in SEQ ID NO.1. The fusion protein is obtained by sequentially connecting the following modules in series: functional domain 1 of fibronectin, hydrophilic region 1 of elastin, functional domain 1 of mussel adhesive protein, hydrophilic region 2 of elastin, functional domain 2 of fibronectin, hydrophilic region 3 of elastin, functional domain 2 of mussel adhesive protein, hydrophilic region 4 of elastin, and integrin-binding region of elastin. The present invention constructs a fusion protein of fibronectin, elastin and mussel adhesive protein, optimizes the nucleotide sequence of the fusion protein, can significantly improve the relative migration rate of keratinocytes, increase the expression level of repair-related genes of HaCat cells, reduce the secretion amount of skin irritation factors, increase the inhibition rate of hyaluronidase, and improve skin repair and soothing ability.

Provided herein are CIB1 (calcium and integrin binding 1) inhibitors and methods of use. The compounds are useful in treating, ameliorating, and / or preventing thrombotic conditions, disease, and disorders. The compounds are also useful in treating, ameliorating, and / or preventing cancer, neurodegenerative diseases, immune system diseases, and inflammation.

Fusion polypeptides including at least one Fc binding domain linked to at least one integrin binding domain are provided. In some embodiments, the at least one Fc binding domain is one or more Fc binding domains from Protein A, Protein G, or Protein Z and the at least one integrin binding domain comprises one or more fibronectin type III domains (for example repeats 12-14 of fibronectin type III domains and optionally the connecting segment of fibronectin). Protein complexes including the polypeptide and one or more antibodies are also provided. Methods of using the polypeptide and / or polypeptide:antibody complex are provided, including treating a subject with a tumor, inducing an immune response to a tumor, and / or targeting an antibody to a tumor cell.

This invention relates to the field of biomimetic nanozymes and their preparation technology, disclosing a biomimetic nanozyme, its preparation method, and its applications. A peptide-functionalized biomimetic nanozyme (HRPL) is obtained by loading rapamycin onto HMPB nanozymes, coating the surface with a platelet membrane, and functionalizing it with the integrin-binding peptide LXW7. The binding of the platelet membrane to the LXW7 peptide enables targeted delivery to the site of endothelial injury, promoting endothelial repair and re-epithelialization. In an acidic inflammatory microenvironment, HRPL releases rapamycin, inhibiting smooth muscle cell proliferation and migration, and preventing restenosis. HRPL also scavenges reactive oxygen species, reducing oxidative stress and local inflammation, thereby improving the vascular microenvironment. The therapeutic effect was evaluated using a typical rat carotid balloon injury model. This dual-targeting mechanism not only promotes endothelial repair but also reduces restenosis and inflammation, showing significant clinical therapeutic potential. Especially after stent implantation, HRPL helps improve prognosis, reduce complications, and restore vascular homeostasis.